Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kerschan-Schindl, K; Haschka, J; Obermayer-Pietsch, B; Gasser, RW; Dimai, HP; Fahrleitner-Pammer, A; Dobnig, H; Roschger, P; Preisinger, E; Klaushofer, K; Resch, H; Pietschmann, P.
How long should women with postmenopausal osteoporosis be treated with a bisphosphonate?
Horm Metab Res. 2013; 45(9):621-628
Doi: 10.1055/s-0033-1345207
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Dimai Hans Peter
- Dobnig Harald
- Fahrleitner-Pammer Astrid
- Obermayer-Pietsch Barbara
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Bisphosphonates are very frequently prescribed to women suffering from postmenopausal osteoporosis with or without fragility fractures. The present review was aimed to update the available information on the most efficient treatment duration. Studies on bisphosphonate treatment duration were identified by Medline up to January 2013. Bisphosphonates are very effective in the short as well as in the medium-term. However, the optimal duration of use has not been determined yet. Therefore, this review summarizes the long-term effects of bisphosphonates on surrogate parameters of fracture prevention, bone mineral density measurements, and bone turnover markers. An initial treatment period of 3-5 years is recommended. Then, the patient has to be re-evaluated for fracture risk, which depends on fracture status as well as on other health issues. Beyond that, life style factors such as regular physical activity as well as a sufficient intake of calcium and vitamin D or, if necessary supplementation of calcium and/or vitamin D play an essential part in fracture prevention. © Georg Thieme Verlag KG Stuttgart · New York.
- Find related publications in this database (using NLM MeSH Indexing)
- Biological Markers - metabolism
- Bone Remodeling - drug effects
- Diphosphonates - administration & dosage Diphosphonates - adverse effects Diphosphonates - pharmacology Diphosphonates - therapeutic use
- Female -
- Humans -
- Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology
- Time Factors -
- Withholding Treatment -
- Find related publications in this database (Keywords)
- bisphosphonate
- long-term treatment
- biomarkers
- bone mineral density
- bone mineralization density distribution
- fragility fracture